Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer

INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg...

Descripción completa

Detalles Bibliográficos
Autores principales: Yanai, Yoshinori, Kosaka, Takeo, Hongo, Hiroshi, Oya, Mototsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292133/
https://www.ncbi.nlm.nih.gov/pubmed/32743408
http://dx.doi.org/10.1002/iju5.12073
_version_ 1783546045226024960
author Yanai, Yoshinori
Kosaka, Takeo
Hongo, Hiroshi
Oya, Mototsugu
author_facet Yanai, Yoshinori
Kosaka, Takeo
Hongo, Hiroshi
Oya, Mototsugu
author_sort Yanai, Yoshinori
collection PubMed
description INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate‐specific antigen response. Follow‐up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer.
format Online
Article
Text
id pubmed-7292133
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-72921332020-07-30 Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer Yanai, Yoshinori Kosaka, Takeo Hongo, Hiroshi Oya, Mototsugu IJU Case Rep Case Reports INTRODUCTION: Abiraterone acetate in combination with prednisone is now widely used for the treatment of castration‐resistant prostate cancer. CASE PRESENTATION: A 62‐year‐old patient with a bone metastatic castration‐resistant prostate cancer was started on abiraterone acetate at a dose of 1000 mg a day along with 10 mg prednisone. In spite of castrate testosterone level, the laboratory test showed a relatively high level of serum testosterone, which was 21 ng/dL. Within 6 months, the patient achieved a complete prostate‐specific antigen response. Follow‐up bone scintigraphy demonstrated no area of intense uptake. He had a history of hyperlipidemia and was started on atorvastatin at home just after starting abiraterone acetate. CONCLUSION: This report is a rare case of a clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer. John Wiley and Sons Inc. 2019-05-09 /pmc/articles/PMC7292133/ /pubmed/32743408 http://dx.doi.org/10.1002/iju5.12073 Text en © 2019 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Case Reports
Yanai, Yoshinori
Kosaka, Takeo
Hongo, Hiroshi
Oya, Mototsugu
Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title_full Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title_fullStr Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title_full_unstemmed Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title_short Clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
title_sort clinically complete response to abiraterone acetate in a patient with metastatic castration‐resistant prostate cancer
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292133/
https://www.ncbi.nlm.nih.gov/pubmed/32743408
http://dx.doi.org/10.1002/iju5.12073
work_keys_str_mv AT yanaiyoshinori clinicallycompleteresponsetoabirateroneacetateinapatientwithmetastaticcastrationresistantprostatecancer
AT kosakatakeo clinicallycompleteresponsetoabirateroneacetateinapatientwithmetastaticcastrationresistantprostatecancer
AT hongohiroshi clinicallycompleteresponsetoabirateroneacetateinapatientwithmetastaticcastrationresistantprostatecancer
AT oyamototsugu clinicallycompleteresponsetoabirateroneacetateinapatientwithmetastaticcastrationresistantprostatecancer

Ejemplares similares